冠心病患者血小板聚集功能及噻氯匹啶作用的观察  

Study of platelet aggregations in patients with coronary heart disease and the effect of ticlopidine treatment

作　　者：李玉杰[1] 麦炜颐[1] 曾群英[1] 何清[1] 刘莉莉 

机构地区：[1]广州中山医科大学附属第一医院,广东广州510080

出　　处：《中国病理生理杂志》2000年第8期702-704,共3页Chinese Journal of Pathophysiology

摘　　要：目的 :探讨冠心病患者血小板聚集功能以及噻氯匹啶对此过程的抑制作用。方法 :应用比浊法测量冠心病患者服药前后 ,由二磷酸腺苷 (ADP)、肾上腺素 (EPI)、胶原 (Coll)和磷酯花生四烯酸 (ACA)诱导的血小板聚集功能。结果 :患病组ADP、EPI诱导的最大血小板聚集率 (0 78± 0 2 3 ,0 86± 0 2 5 )明显高于对照组 (0 6 5±0 19,P <0 0 5 ;0 73± 0 2 1,P <0 0 5 ) ,且被噻氯匹啶明显抑制 (0 6 8± 0 18,P <0 0 5 ;0 75± 0 2 0 ,P <0 0 5 )。而两组间Coll和ACA诱导的最大血小板聚集率无明显差异 ,且患病组治疗前后无明显差异。结论 :冠心病患者血小板聚集功能明显增强 。AIM: To investigate the platelet aggregations in patients with coronary heart disease(CHD) and the effect of ticlopidine treatment. METHODS: Platelet aggregations induced by adenosine diphosphate(ADP), epinephrine(EPI), collagen(Coll), arachidonic acid(ACA) in CHD group before and after ticlopidine treatment were measured by turbidity assay. RESULTS: Maximum ratios of platelet aggregations (max%) induced by ADP,EPI in CHD group (0.78±0.23,0.86±0.25) were significantly higher than that of control group (0.65±0.19,0.73±0.21, P< 0.05). After the treatment with ticlopidine, they were lowered obviously (0.68±0.18, P< 0.05;0.75±0.20, P< 0.05). There were no difference in max% induced by Coll and ACA between two groups and there were no significantly changes of max% induced by Coll and ACA by ticlopidine in CHD group. CONCLUSION: The platelet aggregations were increased in patients with coronary heart disease and could be inhibited by ticlopidine.

关 键 词：血小板聚集 抑制剂 噻氯匹啶 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]